leisure time -WSS

leisure time

author：Wikipedia 2025-09-30 15:22:46 - browse：87

In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

A date for the meeting has not been set yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Change Healthcare: What is it, why does its cyberattack matter?

WSS

Does Paxlovid work in people vaccinated against Covid

Ozempic has benefits for kidney disease as well as diabetes

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Medicare Advantage coverage denials need scrutiny, senators say

STAT Virtual Event: JPM Recap, Live!

Immune cells and nerve overgrowth may explain recurring UTI pain

explore

leisure time

leisure time

Heart attack and stroke risk calculators need revising

Arena BioWorks launches in Cambridge to speed drug discovery

Apple is now the first public company to be valued at $3 trillion

American taxpayers paid $1.8 trillion in health care costs in 2022

DIEP, the 'gold standard' of breast reconstruction, is under threat

Immune cells and nerve overgrowth may explain recurring UTI pain

Guidelines to prevent youth baseball injuries need more muscle

Nonprofit, backed by Microsoft, to certify AI tools in health care

After affirmative action ruling, medical educators look to 'holistic review'

Longer MASH drug regimen improved liver, Akero study finds

focus

Immune cells and nerve overgrowth may explain recurring UTI pain

Harvard's David Sinclair gets blowback over aging

Harvard's David Sinclair gets blowback over aging

At JPM 2024, hospital systems pitch financial strength to investors

Life science postdocs should get big pay hike, NIH panel says

IVF doctors demand details after CooperSurgical lawsuit

leisure time

knowledge

focus

knowledge